{
    "name": "lefamulin",
    "comment": "Rx",
    "other_names": [
        "Xenleta"
    ],
    "classes": [
        "Pleuromutilins"
    ],
    "source": "https://reference.medscape.com/drug/xenleta-lefamulin-1000335",
    "pregnancy": {
        "common": [
            "Based on animal studies, may cause fetal harm",
            "Verify pregnancy status in women of reproductive potential before starting treatment"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Animal studies indicate that IV administration during organogenesis resulted in an increased incidence of prenatal mortality at mean maternal exposures 0.9 times the mean exposure in clinical patients (based on AUC[0-24h]), decreased fetal body weights, apparent delay in sexual maturation that suggests treatment-related developmental delay, and malformations"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Advise females of reproductive potential to use contraception during treatment and for 2 days after final dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data are available on the presence of lefamulin in human milk, the effects on the breastfed infant, or the effects on milk production",
            "Available data in animals have shown lefamulin excreted in milk",
            "If a drug is present in animal milk, it is likely the drug will be present in human milk",
            "Owing to the potential for serious adverse effects, instruct lactating women to pump and discard milk for the duration of treatment and for 2 days after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Coadministration with sensitive CYP3A4 substrates that prolong QT interval"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Prescribing antibiotics in the absence of proven or strongly suspected bacterial infection increases risk of drug-resistant bacteria developing",
                "C difficile",
                "-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including lefamulin; if suspected or confirmed, ongoing antibacterial drug use not directed against ",
                "C difficile",
                " may need to be discontinued and treatment modalities specific for ",
                "C difficile",
                " initiated; evaluate patients who develop diarrhea",
                "Based on animal studies, may cause fetal harm"
            ],
            "specific": [
                {
                    "type": "QT prolongation",
                    "description": [
                        "Potential to prolong QT interval",
                        "Avoid in patients with known QT prolongation, ventricular arrhythmias including torsades de pointes, or receiving other drugs known to prolong QT interval (eg, Class IA or Class III antiarrhythmics, antipsychotics, erythromycin, pimozide, moxifloxacin, TCAs)",
                        "In patients with hepatic impairment or renal failure who require dialysis, metabolic disturbances associated with renal failure may lead to QT prolongation",
                        "If unable to avoid use in specific populations predisposed to QT prolongation or those receiving another drug that prolongs the QT interval, ECG monitoring is recommended during treatment",
                        "The magnitude of QT prolongation may increase with increasing lefamulin concentrations or increasing IV infusion rate; do not exceed recommended dose or infusion rate"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Lefamulin is a CYP3A4 and P-gp substrate; it is also a moderate CYP3A4 inhibitor",
                        "Strong or moderate CYP3A or P-gp inducers: Avoid coadministration",
                        "Strong CYP3A or P-gp inhibitors: Avoid coadministration",
                        "Moderate CYP3A or P-gp inhibitors: Monitor for lefamulin adverse effects",
                        "Sensitive CYP3A4 substrates that prolong QT interval: Contraindicated",
                        "Other sensitive CYP3A4 substrates: Monitor for adverse effects of sensitive CYP3A4 substrates if coadministered with lefamulin tablets (injection does not affect exposure of CYP3A4 substrates",
                        "Other drugs that prolong QT interval: If unable to avoid, ECG monitoring is recommended during treatment"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "thrombocytopenia",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Atrial fibrillation",
            "percent": null
        },
        {
            "name": "palpitations",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "constipation",
            "percent": null
        },
        {
            "name": "dyspepsia",
            "percent": null
        },
        {
            "name": "epigastric discomfort",
            "percent": null
        },
        {
            "name": "erosive gastritis",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Clostridioides",
            "percent": null
        },
        {
            "name": "Clostridium",
            "percent": null
        },
        {
            "name": "difficile colitis",
            "percent": null
        },
        {
            "name": "oropharyngeal candidiasis",
            "percent": null
        },
        {
            "name": "vulvovaginal candidiasis",
            "percent": null
        },
        {
            "name": "Investigations",
            "percent": null
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": null
        },
        {
            "name": "creatine phosphokinase increased",
            "percent": null
        },
        {
            "name": "electrocardiogram QT prolonged",
            "percent": null
        },
        {
            "name": "gamma",
            "percent": null
        },
        {
            "name": "glutamyl transferase increased",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Somnolence",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Urinary retention",
            "percent": null
        }
    ]
}